1. Linch M*, Goh G*, Hiley C, Shanmugabavan Y, McGranahan N, Rowan A, Wong Y-N-S, King H, Furness A, Freeman A, Linares J, Akarca A, Herrero J, Rosenthal R, Harder N, Schmidt G, Wilson G, Birkbak N.J, Mitter R, Dentro S, Cathcart P, Arya M, Johnston E, Scott R, Hung M, Emberton M, Attard G, Szallasi Z, Punwani S, Quezada S, Marafioti T, Gerlinger M, Ahmed H, Swanton C. Intratumoural evolutionary landscape of high risk prostate cancer: The PROGENY study of genomic and immune parameters. Ann Oncol. 2017 Oct; 28(10):2472-2480
2. Wong S, Joshi K, Pule M, Peggs K, Swanton C, Quezada S, Linch M. Evolving adoptive cellular therapies in urological malignancies. Lancet Oncology. 2017 Jun;18(6):e341-e353. 
3. Soriano EV, Ivanova ME, Fletcher G, Riou P, Knowles PP, Barnouin K, Purkiss A, Kostelecky B, Saiu P, Linch M, Elbediwy A, Kjær S, O'Reilly N, Snijders AP, Parker PJ, Thompson BJ, McDonald NQ. aPKC Inhibition by Par3 CR3 Flanking Regions Controls Substrate Access and Underpins Apical-Junctional Polarization. Dev Cell. 2016 Aug 22;38(4):384-98.
4. Yousaf N, Harris S, Martin J, Stanway S, Ifijen M, Linch M, Al Muderis Omar, Fisher C, Judson I, Benson C. First line palliative chemotherapy in elderly patients with advanced soft tissue sarcoma. Clin Sarcoma Res. 2015 Mar 24;5:10.
5. Martin-Liberal J, Cameron A, Claus J, Parker PJ, Linch M. Targeting protein kinase C in sarcoma. Biochim Biophys Acta. 2014 Dec; 1846(2): 547-559. 
6. Linch M, Hayes A. PDT with a glucose-conjugated chlorin for GIST-Letter. Mol Cancer Ther 2014 Nov;13(11): 2763. 
7. Linch M, Gennatas S, Kazikin S, Iqbal J, Gunapala R, Priest K, Severn J, Norton A, Ayite B, Bhosle J, O’Brien M, Popat S. Mesothelin is a prognostic indicator for patients with malignant mesothelioma in routine clinical practice BMC Cancer. 2014 Sep 17;14(1):674.
8. Rossé C, Lodillinsky C, Fuhrmann L, Nourieh M, Monteiro P, Irondelle M, Lagoutte E, Vacher S, Waharte F, Paul-Gilloteaux P, Romao M, Sengmanivong L, Linch M, van Lint J, Raposo G, Vincent-Salomon A, Bièche I, Parker PJ, Chavrier P. Control of MT1-MMP transport by atypical PKC during breast-cancer progression. Proc Natl Acad Sci U S A. 2014 May 6; 111(18): E1872-1879.
9. Linch M, Miah A, Thway K, Judson IR, Benson C. Systemic treatment of soft tissue sarcoma: current gold standard and novel therapies. Nat Rev Clin Oncol. 2014 Apr;11(4):187-202. 
10. Gough N, Miah A, Linch M. Oncological management of cancer pain. Curr Opin Support Palliat Care. 2014 Jun;8(2):102-111.
11. Linch M, Riou P, Claus J, Cameron A, de Naurois J, Larinjani B, Ng T, McDonald N, Parker P. Functional implications of assigned, assumed and assembled PKC structures. Biochem Soc Trans. 2014 Feb; 42(1):35-41.
12. Linch M, Sanz-Garcia M, Rosse C, Riou P, Peel N, Madsen C, Sahai E, Downward J, Khwaja A, Dillon C, Roffey J, Cameron A, Parker PJ. Regulation of polarized morphogenesis by protein kinase C iota in oncogenic epithelial spheroids. Carcinogenesis. 2014 Feb;35(2):396-406. 
13. Linch M, Sanz-Garcia M, Soriano E, Zhang Y, Riou P, Rosse C, Cameron A, Knowles P, Purkiss A, Kjaer S, McDonald NQ, Parker PJ. A cancer-associated mutation in atypical protein kinase C iota occurs in a substrate-specific recruitment motif. Sci Signal. 2013 Sep;6(293):ra82.